Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
ALEC Alector Inc
- Stocks
- Healthcare
- NASDAQ: ALEC
Price (delayed)
$1.47
Market cap
$146.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.25
Enterprise value
$148.22M
Alector is a clinical stage biotechnology company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. The Company is developing a broad portfolio of innate immune system
Highlights
ALEC's EPS is up by 9% YoY
The debt has grown by 9% YoY but it has contracted by 3.5% from the previous quarter
The equity has decreased by 47% YoY and by 25% QoQ
ALEC's gross profit is down by 12% from the previous quarter and by 8% YoY
Key stats
What are the main financial stats of ALEC
Market
Valuations
Earnings
Shares outstanding
99.99M
Market cap
$146.99M
Enterprise value
$148.22M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.54
Price to sales (P/S)
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
Revenue
$88.34M
Gross profit
$88.34M
Operating income
-$145.98M
Net income
-$123.44M
EBIT
-$123.32M
EBITDA
-$114.92M
Free cash flow
-$230.08M
Per share
Balance sheet
Liquidity
EPS
-$1.25
EPS diluted
-$1.25
Free cash flow per share
-$2.31
Book value per share
$0.95
Revenue per share
$0.89
TBVPS
$4.11
Total assets
$408.3M
Total liabilities
$313.69M
Debt
$41.05M
Equity
$94.61M
Working capital
$256.88M
Debt to equity
0.43
Current ratio
3.34
Quick ratio
3.25
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
-130.1%
Gross margin
100%
Net margin
-139.7%
Operating margin
-165.3%
Return on assets
-25.1%
Return on equity
-100.6%
Return on invested capital
-34.5%
Return on capital employed
-41.3%
Return on sales
-139.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALEC stock price
How has the Alector stock price performed over time
Intraday
0.68%
1 week
-4.55%
1 month
7.3%
1 year
-64.92%
YTD
-22.22%
QTD
19.51%
Financial performance
How have Alector's revenue and profit performed over time
Revenue
$88.34M
Gross profit
$88.34M
Operating income
-$145.98M
Net income
-$123.44M
Gross margin
100%
Net margin
-139.7%
The net margin has contracted by 18% from the previous quarter and by 12% YoY
ALEC's operating margin is down by 15% since the previous quarter and by 10% year-on-year
ALEC's gross profit is down by 12% from the previous quarter and by 8% YoY
The revenue has declined by 12% since the previous quarter and by 8% year-on-year
Price vs fundamentals
How does ALEC's price correlate with its fundamentals
Growth
What is Alector's growth rate over time
Valuation
What is Alector stock price valuation
P/E
N/A
P/B
1.54
P/S
1.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.68
ALEC's EPS is up by 9% YoY
ALEC's P/B is 62% below its 5-year quarterly average of 4.0 and 36% below its last 4 quarters average of 2.4
The equity has decreased by 47% YoY and by 25% QoQ
The stock's price to sales (P/S) is 93% less than its 5-year quarterly average of 22.1 and 64% less than its last 4 quarters average of 4.6
The revenue has declined by 12% since the previous quarter and by 8% year-on-year
Efficiency
How efficient is Alector business performance
The return on equity has declined by 40% year-on-year and by 21% since the previous quarter
Alector's ROA has decreased by 37% YoY and by 16% from the previous quarter
The return on invested capital has declined by 32% year-on-year and by 13% since the previous quarter
ALEC's ROS is down by 18% from the previous quarter and by 16% YoY
Dividends
What is ALEC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALEC.
Financial health
How did Alector financials performed over time
ALEC's total assets is 30% greater than its total liabilities
ALEC's total assets is down by 36% year-on-year and by 13% since the previous quarter
ALEC's total liabilities is down by 31% year-on-year and by 8% since the previous quarter
The debt is 57% less than the equity
The debt to equity has soared by 105% year-on-year and by 26% since the previous quarter
The equity has decreased by 47% YoY and by 25% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.